Logo

Active Biotech Reports First Patient Dosing in the P-Ib/IIa Study of Tasquinimod for the Treatment of Multiple Myeloma

Share this

Active Biotech Reports First Patient Dosing in the P-Ib/IIa Study of Tasquinimod for the Treatment of Multiple Myeloma

Shots:

  • The first patient has been dosed in the combination part of the P-Ib/IIa study to evaluate tasquinimod + IRd as antimyeloma agents in patients with r/r MM. The study is being conducted with the Abramson Cancer Center of the University of Pennsylvania
  • The 2EPs will include antimyeloma activity. In previous studies, tasquinimod monothx. was generally well tolerated & established treatment schedule along with safety profile of tasquiniomod
  • The results also showed a clear therapeutic potential in preclinical models as monothx. and in combination with standard multiple myeloma therapy. Tasquinimod is being developed as a new immunomodulatory treatment for hematological malignancies in MM

to­Ref: Globenewswire | Image: Huntington's Disease News

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions